CA1 and rheumatoid arthritis: In this context, a group of small-molecule hybrids known as CAI–CORM hybrids, which combine a carbonic anhydrase inhibitor (CAI) with a CORM tail section, were described by Berrino et al. [22] as having potential applications in the treatment of rheumatoid arthritis.